Therapeutic compounds comprised of anti-Fc receptor antibodies
AssigneeMedarex, Inc.
InventorsYashwant M. Deo, Joel Goldstein, Robert Graziano, Chezian Somasundaram
Life of this patent
Estimating the term…
Abstract
Multispecific multivalent molecules which are specific to an Fc receptor (FcR), and therapeutic uses and therapeutic uses and methods for making the molecules are described.
Claims18
A method of inducing antibody-dependent cellular cytotoxicity (ADCC) against a tumor cell which tumor cell is characterized by overexpression of HER 2/neu or epidermal growth factor receptor (EGFR), comprising contacting the tumor cell with a multispecific protein molecule comprising:
- an anti-Fc receptor n(FcR) antibody or an antigen binding fragment thereof;
- a portion which binds to HER 2/neu;
- and
- a portion which binds to EGFR.
A method of inducing antibody-dependent cellular cytotoxicity (ADCC) against a tumor cell characterized by overexpression of a surface receptor selected from the group consisting of receptors for HER 2, HER 3, HER 4, epidermal growth factor (EGF) and bombesin, comprising contacting the tumor cell with a fusion protein comprising:
- antibody H22 produced by the cell line having an ATCC accession number CRL 1117 or an antigen binding fragment thereof;
- and
- at least one ligand which binds to said surface receptor.
A method of inducing antibody-dependent cellular cytotoxicity (ADCC) against a tumor cell, comprising contacting the tumor cell with a multispecific single chain antibody H22 having the amino acid sequence shown in FIG. 39 (SEQ.ID. No:
- 14), and a portion which binds to the tumor cell.
Dependencies are inferred from the claim text.